890147-32-7

Basic information

• Product Name: 3-(dibenzylamino)-2,2-difluoropropan-1-ol
• Synonyms: 3-(dibenzylamino)-2,2-difluoropropan-1-ol
• CAS NO: 890147-32-7
• Molecular Formula: C17H19F2NO
• Molecular Weight: 291.341
• Mol File: 890147-32-7.mol

Chemical Properties

• CAS DataBase Reference: 3-(dibenzylamino)-2,2-difluoropropan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(dibenzylamino)-2,2-difluoropropan-1-ol(890147-32-7)
• EPA Substance Registry System: 3-(dibenzylamino)-2,2-difluoropropan-1-ol(890147-32-7)

Safety Data

• Hazardous Substances Data: 890147-32-7(Hazardous Substances Data)

Upstream product

• 57684-32-9 N-((1 H-benzo[d][1,2,3]triazol-1-yl)methyl)-N-benzyl-1-phenylmethanamine 
• 103-49-1 dibenzylamine 
• 541547-36-8 ethyl N,N-(dibenzyl)-2,2-difluoro-3,3-aminopropanoate 
• 890147-31-6 methyl 3-(N,N-dibenzylamino)-2,2-difluoropropionate 

Relevant articles and documents

NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

Heterocyclic compound

本發明提供一種具有CDK8/19抑制活性之雜環化合物。本發明提供一種如下式代表之化合物(其中各代號均如本文之定義)或其鹽。 The present invention provides a heterocyclic compound possessing CDK8/19 inhibitory activity. The present invention provides a compound represented by the formula wherein each symbol is as defined herein, or a salt thereof.

HETEROCYCLIC CETP INHIBITORS

Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.

Methods and fluorinated compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease.